Associated Genetic Biomarkers
NCI Definition: A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis). 
Lymphoproliferative disorders most frequently harbor alterations in KMT2D, CREBBP, TP53, BCL2, and TET2 .
KMT2D Mutation, CREBBP Mutation, TP53 Mutation, TP53 c.217-c.1178 Missense, and TP53 Missense are the most common alterations in lymphoproliferative disorder .
There are 5 clinical trials for lymphoproliferative disorder, of which 4 are open and 1 is completed or closed. Of the trials that contain lymphoproliferative disorder as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (1 open).
Nivolumab, allogeneic epstein-barr virus-specific cytotoxic t-lymphocytes, and allogeneic lmp1/lmp2-specific cytotoxic t-lymphocytes are the most common interventions in lymphoproliferative disorder clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.